` RAC (Race Oncology Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

RAC
vs
S
S&P/ASX 300

Over the past 12 months, RAC has underperformed S&P/ASX 300, delivering a return of -26% compared to the S&P/ASX 300's +13% growth.

Stocks Performance
RAC vs S&P/ASX 300

Loading
RAC
S&P/ASX 300
Add Stock
www.alphaspread.com

Performance Gap
RAC vs S&P/ASX 300

Loading
RAC
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
RAC vs S&P/ASX 300

Loading
RAC
S&P/ASX 300
Add Stock

Competitors Performance
Race Oncology Ltd vs Peers

S&P/ASX 300
RAC
ABBV
AMGN
GILD
VRTX
Add Stock

Race Oncology Ltd
Glance View

Market Cap
200.6m AUD
Industry
Biotechnology

Race Oncology Ltd. is a precision oncology company, with the phase 2/3 cancer drug, Bisantrene, which is a potent small molecule inhibitor of the Fatso (FTO) protein. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-07-13. Bisantrene is a small molecule inhibitor of the fat mass and obesity associated (FTO) protein. The firm is targeting the use of Bisantrene in melanoma and clear cell renal cell carcinoma (kidney cancer), both frequent FTO-driven cancers. Race also has clinical data for the use of Bisantrene in Acute Myeloid Leukaemia (AML), Breast and Ovarian cancers.

RAC Intrinsic Value
0.987 AUD
Overvaluation 15%
Intrinsic Value
Price
Back to Top